Thermo Fisher Scientific’s clinical research business named `Best CRO’ at Vaccine Excellence Awards

New Delhi: The PPD clinical research business of Thermo Fisher Scientific was named “Best Contract Research Organization” at the 15th annual Vaccine Industry Excellence (ViE) Awards during the 2022 World Vaccine Congress, recognizing its success in helping customers develop safe and effective vaccines to improve health and save lives.

The honour marks the business’ second consecutive year earning “Best CRO” at the ViE Awards and follows recognition at the Citeline Awards as “Clinical Research Team of the Year” with Moderna, whose pioneering mRNA vaccine for Covid has been administered to hundreds of millions globally.

With more than 30 years of commercial and government vaccine experience, the business has conducted vaccine studies in more than 90 countries and works with customers across a wide spectrum of vaccine programs, from legacy vaccines to emerging pathogens. The business is a recognized leader in managing Covid-19 and mRNA research programs.

“We are grateful for the opportunity to partner with our customers to advance their vaccine development programs and make a positive impact on the health of people across the globe,” said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “Winning industry honours for our vaccine expertise is a testament to the talent and commitment of our colleagues worldwide, whose experience and innovative mindset make this success possible.”

The business provides end-to-end clinical development services, including a dedicated vaccines delivery unit and vaccine sciences, bioanalytical and central laboratories enabling customers to accelerate vaccine development timelines. The business is strategically positioned with a priority site network of more than 2,000 experienced sites and 32 depots globally for product and logistics management. The vaccine sciences lab is fully integrated with bioanalytical, central and GMP labs and clinical teams. Additionally, the business’ Preclarus visualization technology platform offers near real-time data access and trend analysis to integrated clinical and lab data across an entire study.